

Brenda De Winter

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4527471/publications.pdf>

Version: 2024-02-01

52
papers

1,658
citations

304743

22
h-index

302126

39
g-index

52
all docs

52
docs citations

52
times ranked

1928
citing authors

#	ARTICLE	IF	CITATIONS
1	Comparison of antipsychotic drug use among Dutch Youth before and after implementation of the Youth Act (2010–2019). <i>European Child and Adolescent Psychiatry</i> , 2023, 32, 1427-1434.	4.7	4
2	High antibody response in relation to immunosuppressive blood levels in liver transplant recipients after SARS-CoV-2 vaccination: an observational, cohort study. <i>Gut</i> , 2022, 71, 2605-2608.	12.1	3
3	Monitoring intracellular tacrolimus concentrations and its relationship with rejection in the early phase after renal transplantation. <i>Clinical Biochemistry</i> , 2022, 101, 9-15.	1.9	9
4	Validation of a dried blood spot method to measure tacrolimus concentrations in small volumes of mouse blood. <i>Bioanalysis</i> , 2022, 14, 441-449.	1.5	1
5	A Population Pharmacokinetic Model of Whole-Blood and Intracellular Tacrolimus in Kidney Transplant Recipients. <i>European Journal of Drug Metabolism and Pharmacokinetics</i> , 2022, 47, 523-535.	1.6	4
6	Body composition is associated with tacrolimus pharmacokinetics in kidney transplant recipients. <i>European Journal of Clinical Pharmacology</i> , 2022, 78, 1273-1287.	1.9	2
7	Risperidone plasma concentrations are associated with side effects and effectiveness in children and adolescents with autism spectrum disorder. <i>British Journal of Clinical Pharmacology</i> , 2021, 87, 1069-1081.	2.4	29
8	Monitoring the tacrolimus concentration in peripheral blood mononuclear cells of kidney transplant recipients. <i>British Journal of Clinical Pharmacology</i> , 2021, 87, 1918-1929.	2.4	20
9	Determining the therapeutic range for ribavirin in transplant recipients with chronic hepatitis E virus infection. <i>Journal of Viral Hepatitis</i> , 2021, 28, 431-435.	2.0	7
10	Avoiding Tacrolimus Underexposure and Overexposure with a Dosing Algorithm for Renal Transplant Recipients: A Single Arm Prospective Intervention Trial. <i>Clinical Pharmacology and Therapeutics</i> , 2021, 110, 169-178.	4.7	24
11	Parametric and Nonparametric Population Pharmacokinetic Models to Assess Probability of Target Attainment of Imipenem Concentrations in Critically Ill Patients. <i>Pharmaceutics</i> , 2021, 13, 2170.	4.5	2
12	Population Pharmacokinetics of Intravenous Salbutamol in Children with Refractory Status Asthmaticus. <i>Clinical Pharmacokinetics</i> , 2020, 59, 257-264.	3.5	10
13	A Population Pharmacokinetic Model Does Not Predict the Optimal Starting Dose of Tacrolimus in Pediatric Renal Transplant Recipients in a Prospective Study: Lessons Learned and Model Improvement. <i>Clinical Pharmacokinetics</i> , 2020, 59, 591-603.	3.5	14
14	Measuring Intracellular Concentrations of Calcineurin Inhibitors: Expert Consensus from the International Association of Therapeutic Drug Monitoring and Clinical Toxicology Expert Panel. <i>Therapeutic Drug Monitoring</i> , 2020, 42, 665-670.	2.0	22
15	Finger-Prick Blood Sampling for Therapeutic Drug Monitoring: Be Aware of Skin Contamination by Nebulized Drugs. <i>Therapeutic Drug Monitoring</i> , 2020, 42, 512-513.	2.0	0
16	Use of amlodipine oral solution for the treatment of hypertension in children. <i>International Journal of Clinical Pharmacy</i> , 2020, 42, 848-852.	2.1	3
17	Pharmacokinetics and pharmacogenetics of high-dose methotrexate in Chinese adult patients with non-Hodgkin lymphoma: a population analysis. <i>Cancer Chemotherapy and Pharmacology</i> , 2020, 85, 881-897.	2.3	16
18	The pharmacogenetics of tacrolimus and its implications for personalized therapy in kidney transplant recipients. <i>Expert Review of Precision Medicine and Drug Development</i> , 2020, 5, 313-316.	0.7	4

#	ARTICLE	IF	CITATIONS
19	Population Pharmacokinetics of Imipenem in Critically Ill Patients: A Parametric and Nonparametric Model Converge on CKD-EPI Estimated Glomerular Filtration Rate as an Impactful Covariate. <i>Clinical Pharmacokinetics</i> , 2020, 59, 885-898.	3.5	9
20	Population pharmacokinetics and target attainment of ciprofloxacin in critically ill patients. <i>European Journal of Clinical Pharmacology</i> , 2020, 76, 957-967.	1.9	19
21	Pipamperone Population Pharmacokinetics Related to Effectiveness and Side Effects in Children and Adolescents. <i>Clinical Pharmacokinetics</i> , 2020, 59, 1393-1405.	3.5	10
22	Immunomonitoring of Tacrolimus in Healthy Volunteers: The First Step from PK- to PD-Based Therapeutic Drug Monitoring?. <i>International Journal of Molecular Sciences</i> , 2019, 20, 4710.	4.1	12
23	Therapeutic Drug Monitoring of Tacrolimus-Personalized Therapy: Second Consensus Report. <i>Therapeutic Drug Monitoring</i> , 2019, 41, 261-307.	2.0	374
24	A population pharmacokinetic model to predict the individual starting dose of tacrolimus in adult renal transplant recipients. <i>British Journal of Clinical Pharmacology</i> , 2019, 85, 601-615.	2.4	56
25	Highly sensitive and rapid determination of tacrolimus in peripheral blood mononuclear cells by liquid chromatography-tandem mass spectrometry. <i>Biomedical Chromatography</i> , 2019, 33, e4416.	1.7	23
26	Population pharmacokinetic modelling of intravenous paracetamol in fit older people displays extensive unexplained variability. <i>British Journal of Clinical Pharmacology</i> , 2019, 85, 126-135.	2.4	10
27	Converting cyclosporine A from intravenous to oral administration in hematopoietic stem cell transplant recipients and the role of azole antifungals. <i>European Journal of Clinical Pharmacology</i> , 2018, 74, 767-773.	1.9	13
28	Dried Blood Spot Analysis for Therapeutic Drug Monitoring of Antipsychotics: Drawbacks of Its Clinical Application. <i>Therapeutic Drug Monitoring</i> , 2018, 40, 344-350.	2.0	38
29	Dosing ribavirin in hepatitis E-infected solid organ transplant recipients. <i>Pharmacological Research</i> , 2018, 130, 308-315.	7.1	16
30	Highly variable absorption of clavulanic acid during the day: a population pharmacokinetic analysis. <i>Journal of Antimicrobial Chemotherapy</i> , 2018, 73, 469-476.	3.0	15
31	Personalized immunosuppression in elderly renal transplant recipients. <i>Pharmacological Research</i> , 2018, 130, 303-307.	7.1	29
32	A Population Pharmacokinetic Model to Predict the Individual Starting Dose of Tacrolimus Following Pediatric Renal Transplantation. <i>Clinical Pharmacokinetics</i> , 2018, 57, 475-489.	3.5	48
33	Population pharmacodynamic modelling of midazolam induced sedation in terminally ill adult patients. <i>British Journal of Clinical Pharmacology</i> , 2018, 84, 320-330.	2.4	16
34	Prediction of Free from Total Mycophenolic Acid Concentrations in Stable Renal Transplant Patients: A Population-Based Approach. <i>Clinical Pharmacokinetics</i> , 2018, 57, 877-893.	3.5	20
35	<i>CYP3A5</i> and <i>ABCB1</i> polymorphisms in living donors do not impact clinical outcome after kidney transplantation. <i>Pharmacogenomics</i> , 2018, 19, 895-903.	1.3	7
36	Clinical applications of population pharmacokinetic models of antibiotics: Challenges and perspectives. <i>Pharmacological Research</i> , 2018, 134, 280-288.	7.1	94

#	ARTICLE	IF	CITATIONS
37	Hypoalbuminaemia and decreased midazolam clearance in terminally ill adult patients, an inflammatory effect?. <i>British Journal of Clinical Pharmacology</i> , 2017, 83, 1701-1712.	2.4	23
38	Pharmacokinetic considerations related to therapeutic drug monitoring of tacrolimus in kidney transplant patients. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2017, 13, 1225-1236.	3.3	95
39	Population pharmacokinetics of haloperidol in terminally ill adult patients. <i>European Journal of Clinical Pharmacology</i> , 2017, 73, 1271-1277.	1.9	9
40	Overweight Kidney Transplant Recipients Are at Risk of Being Overdosed Following Standard Bodyweight-Based Tacrolimus Starting Dose. <i>Transplantation Direct</i> , 2017, 3, e129.	1.6	30
41	Pharmacokinetic considerations and recommendations in palliative care, with focus on morphine, midazolam and haloperidol. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2016, 12, 669-680.	3.3	41
42	Consideration of the ethnic prevalence of genotypes in the clinical use of tacrolimus. <i>Pharmacogenomics</i> , 2016, 17, 1737-1740.	1.3	26
43	Non-linear absorption pharmacokinetics of amoxicillin: consequences for dosing regimens and clinical breakpoints. <i>Journal of Antimicrobial Chemotherapy</i> , 2016, 71, 2909-2917.	3.0	59
44	POPULATION PHARMACOKINETICS OF INTRAVENOUS ALBUTEROL IN CHILDREN WITH STATUS ASTHMATICUS. <i>Archives of Disease in Childhood</i> , 2016, 101, e1.31-e1.	1.9	0
45	Pharmacokinetics of Morphine, Morphine-3-Glucuronide and Morphine-6-Glucuronide in Terminally Ill Adult Patients. <i>Clinical Pharmacokinetics</i> , 2016, 55, 697-709.	3.5	23
46	Population pharmacokinetic model and Bayesian estimator for two tacrolimus formulations “ twice daily Prograf [®] and once daily Advagraf [®] . <i>British Journal of Clinical Pharmacology</i> , 2011, 71, 391-402.	2.4	93
47	Differences in Clearance of Mycophenolic Acid Among Renal Transplant Recipients, Hematopoietic Stem Cell Transplant Recipients, and Patients With Autoimmune Disease. <i>Therapeutic Drug Monitoring</i> , 2010, 32, 606-614.	2.0	34
48	Pharmacokinetic role of protein binding of mycophenolic acid and its glucuronide metabolite in renal transplant recipients. <i>Journal of Pharmacokinetics and Pharmacodynamics</i> , 2009, 36, 541-564.	1.8	73
49	Limited Sampling Strategies for Therapeutic Drug Monitoring of Mycophenolate Mofetil Therapy in Patients With Autoimmune Disease. <i>Therapeutic Drug Monitoring</i> , 2009, 31, 382-390.	2.0	31
50	Limited Sampling Strategies Drawn Within 3 Hours Postdose Poorly Predict Mycophenolic Acid Area-Under-the-Curve After Enteric-Coated Mycophenolate Sodium. <i>Therapeutic Drug Monitoring</i> , 2009, 31, 585-591.	2.0	27
51	Population Pharmacokinetics of Mycophenolic Acid. <i>Clinical Pharmacokinetics</i> , 2008, 47, 827-838.	3.5	79
52	Therapeutic drug monitoring of mycophenolic acid: does it improve patient outcome?. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2007, 3, 251-261.	3.3	32